Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation

J Am Coll Cardiol. 1998 Aug;32(2):393-7. doi: 10.1016/s0735-1097(98)00226-5.

Abstract

Background: Recent studies of growth hormone supplementation in chronic heart failure have been associated with variable results. Acquired abnormalities of biochemical parameters of the growth hormone insulin-like growth factor I axis have been associated with severe chronic heart failure. There are suggestions of an acquired growth hormone resistance with deficient insulin-like growth factor I in some patients.

Objectives: Therefore, we set out to investigate the clinical and functional status and the degree of cytokine and neurohormonal alteration of chronic heart failure patients with deficient insulin-like growth factor I responses.

Methods: Patients with chronic heart failure were divided into two groups according to their insulin-like growth factor I levels (classified according to the manufacturer's assay range in normal controls): low insulin-like growth factor I <104 (n = 20; 89 +/- 9.6 ng/ml), and normal/high >104 ng/ml (n = 32; 169 +/- 52 ng/ml). Between groups there was no difference in age (low versus high: 65.3 +/- 12.1 versus 61.6 +/- 9.1 years, p = 0.21), body mass index, aerobic capacity (peak oxygen consumption: low versus high: 15.5 +/- 5.2 versus 17.3 +/- 6.3 mL/kg/min, p = 0.23), left ventricular ejection fraction, New York Heart Association classification.

Results: During quadriceps strength testing, patients with low insulin-like growth factor I had reduced absolute strength (-24%), and strength per unit area muscle (- 14%) than patients with normal/high insulin-like growth factor I. Leg muscle cross-sectional area was lower in the low insulin-like growth factor I group (-12% and -13% for right and left legs, respectively). These alterations were accompanied by increased levels of growth hormone (+145%), tumor necrosis factor-alpha (+46%), cortisol/ dehydroepiandrosterone ratio (+60%), noradrenaline (+49%) and adrenaline (+136%) (all at least p < 0.05).

Conclusions: Patients with low insulin-like growth factor I levels show signs of altered body composition, cytokine and neuroendocrine activation, to a greater extent than patients with normal/high levels.

MeSH terms

  • Adrenergic alpha-Agonists / blood
  • Age Factors
  • Aged
  • Anatomy, Cross-Sectional
  • Body Composition / physiology*
  • Body Mass Index
  • Cytokines / blood
  • Cytokines / physiology*
  • Dehydroepiandrosterone / blood
  • Drug Resistance
  • Energy Metabolism / physiology*
  • Epinephrine / blood
  • Heart Failure / metabolism*
  • Heart Failure / physiopathology
  • Human Growth Hormone / physiology
  • Human Growth Hormone / therapeutic use
  • Humans
  • Hydrocortisone / blood
  • Insulin-Like Growth Factor I / deficiency*
  • Insulin-Like Growth Factor I / therapeutic use
  • Leg
  • Middle Aged
  • Muscle Contraction / physiology
  • Muscle, Skeletal / pathology
  • Muscle, Skeletal / physiopathology
  • Neuropeptides / blood
  • Neuropeptides / physiology*
  • Norepinephrine / blood
  • Oxygen Consumption / physiology
  • Stroke Volume / physiology
  • Tumor Necrosis Factor-alpha / analysis
  • Ventricular Function, Left / physiology

Substances

  • Adrenergic alpha-Agonists
  • Cytokines
  • Neuropeptides
  • Tumor Necrosis Factor-alpha
  • Human Growth Hormone
  • Dehydroepiandrosterone
  • Insulin-Like Growth Factor I
  • Hydrocortisone
  • Norepinephrine
  • Epinephrine